321
Oct 12 (Reuters) – Arcus Biosciences Inc: * ANTI-TIGIT DOMVANALIMAB PLUS ANTI-PD-1 ZIMBERELIMAB AND CHEMOTHERAPY SHOWED 26.7 MONTHS OF MEDIAN OVERALL SURVIVAL AS FIRST-LINE TREATMENT OF UNRESECTABLE OR ADVANCED GASTROESOPHAGEAL ADENOCARCINOMAS IN THE PHASE 2 EDGE-GASTRIC STUDY * ARCUS BIOSCIENCES INC – NO UNEXPECTED SAFETY SIGNALS OBSERVED IN STUDY Source text: Further company coverage:
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
